<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dacarbazine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dacarbazine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dacarbazine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9316" href="/d/html/9316.html" rel="external">see "Dacarbazine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12480" href="/d/html/12480.html" rel="external">see "Dacarbazine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708693"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.</p>
<p style="text-indent:-2em;margin-left:2em;">In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression: </span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Hemopoietic depression is the most common toxicity with dacarbazine.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects: </span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Hepatic necrosis has been reported.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Carcinogenic/teratogenic:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046817"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F156250"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b> For oncology uses, details concerning dosing in combination regimens should also be consulted. Dacarbazine in combination with doxorubicin is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">High risk:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ABVD regimen</i>: Children and Adolescents: IV: 375 mg/m<sup>2</sup> over 30 to 60 minutes on Days 1 and 15 of a 28-day treatment cycle for 2 to 6 cycles in combination with doxorubicin, vinblastine, and bleomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35187850','lexi-content-ref-9508171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35187850','lexi-content-ref-9508171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CAPDac consolidation regimen</i>: Children ≥6 years and Adolescents: IV: 250 mg/m<sup>2</sup> on Days 1 to 3 of a 21-day treatment cycle for 4 cycles in combination with cyclophosphamide, brentuximab vedotin, and prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33826362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33826362'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermediate or advanced stage:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bv-AVD-R regimen</i>: Children ≥4 years and Adolescents: IV: 375 mg/m<sup>2</sup> on Days 1 and 15 of a 28-day treatment cycle for 4 to 6 cycles in combination with brentuximab vedotin, doxorubicin, vinblastine, and rituximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35584865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35584865'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>COPDac consolidation regimen</i>: Children and Adolescents: IV: 250 mg/m<sup>2</sup> on Days 1 to 3 of a 28-day treatment cycle for 2 to 4 cycles in combination with prednisone/prednisolone, vincristine, and cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895479'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27a3b2da-dfc1-48c2-b766-5f683d7e043d">Melanoma, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, high-risk: </b>Limited data available: Children ≥10 years and Adolescents: IV: 800 mg/m<sup>2 </sup>over 1 hour on Day 1 of a 21-day treatment cycle for 3 cycles; in combination with vinblastine, cisplatin, and interferon alfa-2b. <b>Note:</b> Administer dacarbazine after vinblastine on Day 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25332243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25332243'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090578"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; experience in adult patients suggests dose adjustment may be necessary; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51090579"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. May cause hepatotoxicity; monitor closely for signs of toxicity.</p></div>
<div class="block doa drugH1Div" id="F156226"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9316" href="/d/html/9316.html" rel="external">see "Dacarbazine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Dacarbazine is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma: </b></p>
<p style="text-indent:-2em;margin-left:4em;">ABVD regimen: <b>IV: </b>375 mg/m<sup>2</sup> on days 1 and 15 every 4 weeks (in combination with doxorubicin, bleomycin, and vinblastine) for 2 to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15199092','lexi-content-ref-20818855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15199092','lexi-content-ref-20818855'])">Ref</a></span>). The number of cycles required and follow-up treatment may be determined by PET scan after 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27332902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27332902'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">A-AVD regimen: <b>IV: </b>375 mg/m<sup>2</sup> on days 1 and 15 every 4 weeks (in combination with brentuximab vedotin, doxorubicin, and vinblastine) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29224502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29224502'])">Ref</a></span>). Administer primary prophylaxis with G-CSF (filgrastim) beginning with cycle 1.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18caf99b-f195-4f15-b158-71b62bb2404f">Melanoma, metastatic malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, metastatic malignant:</b>
<b>IV: </b>250 mg/m<sup>2</sup> over 30 minutes once daily on days 1 to 5 every 3 weeks for up to 12 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10623706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10623706'])">Ref</a></span>) <b>or</b> 850 to 1,000 mg/m<sup>2 </sup>once every 3 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10561349','lexi-content-ref-21639810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10561349','lexi-content-ref-21639810'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bec6b935-37a5-4673-b645-664aedbd0c66">Pancreatic neuroendocrine tumors, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic neuroendocrine tumors, advanced (off-label use):</b>
<b>IV: </b>850 mg/m<sup>2</sup> over 60 to 90 minutes on day 1 every 4 weeks until disease progression or unacceptable toxicity (minimum of 2 cycles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11583197']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11583197'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60a3049d-932f-4cb6-8b42-d79eefa7ea93">Pheochromocytoma, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma, malignant (off-label use):</b> CVD regimen: <b>IV:</b> 600 mg/m<sup>2</sup> once daily for 2 days every 3 or 4 weeks (in combination with cyclophosphamide and vincristine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18780317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18780317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7010e3ba-7b4f-4a1f-86d7-7a0447b9278e">Soft tissue sarcoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma, advanced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">AD regimen: <b>IV: </b>250 mg/m<sup>2</sup>/day as a continuous infusion for 4 days every 3 weeks (total of 1,000 mg/m<sup>2</sup>/cycle) (in combination with doxorubicin); patients received a median of 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8315425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8315425'])">Ref</a></span>) <b>or</b> 187.5 mg/m<sup>2</sup>/day as a continuous infusion for 4 days every 3 weeks (total of 750 mg/m<sup>2</sup>/cycle) (in combination with doxorubicin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2067035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2067035'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">MAID regimen: <b>IV: </b>250 mg/m<sup>2</sup>/day as a continuous infusion for 4 days every 3 weeks (total of 1,000 mg/m<sup>2</sup>/cycle) (in combination with mesna, doxorubicin, and ifosfamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8315425','lexi-content-ref-9529020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8315425','lexi-content-ref-9529020'])">Ref</a></span>). Continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9529020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9529020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gemcitabine/Dacarbazine regimen: <b>IV:</b> 500 mg/m<sup>2 </sup>once every 2 weeks (in combination with gemcitabine) for 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21606430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21606430'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db736476-3208-4376-ac74-a6b81d0d4ea5">Thyroid carcinoma, medullary, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid carcinoma, medullary, advanced or metastatic (off-label use):</b>
<b>IV: </b>200 mg/m<sup>2</sup> once daily for 5 days every 8 weeks (in combination with fluorouracil and alternating with doxorubicin/streptozocin) until disease progression or unacceptable toxicity, or for a total of 6 cycles if tumor response or stabilization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10952773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10952773'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> once daily for 5 days every 6 weeks (in combination with fluorouracil and alternating with streptozocin/fluorouracil) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7530987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7530987'])">Ref</a></span>) <b>or</b> 600 mg/m<sup>2</sup> once daily for 2 days every 3 or 4 weeks (in combination with cyclophosphamide and vincristine); patients received a median of 4 cycles (range: 2 to 17 cycles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8293411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8293411'])">Ref</a></span>) <b>or</b> 250 mg/m<sup>2</sup> over 15 to 30 minutes once daily for 5 days every 4 weeks (in combination with fluorouracil) until disease progression or for a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7826911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7826911'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991623"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:2em;">Kintzel 1995:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 46 to 60 mL/minute: Reduce dose to 80% of usual dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 31 to 45 mL/minute: Reduce dose to 75% of usual dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: Reduce dose to 70% of usual dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Krens 2019:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Consider reducing dose to 70% of usual dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Consider reducing dose to 70% of usual dose.</p></div>
<div class="block doha drugH1Div" id="F50988895"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. May cause hepatotoxicity; monitor closely for signs of toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended.</p></div>
<div class="block adr drugH1Div" id="F156194"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Infusion-site pain</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea and vomiting (&gt;90%), anorexia</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Bone marrow depression (onset: 5 to 7 days; nadir: 7 to 10 days; recovery: 21 to 28 days), leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, anemia, diarrhea, dysgeusia, eosinophilia, erythema, facial flushing, facial paresthesia, flu-like symptoms (fever, myalgia, malaise), hepatic necrosis, increased liver enzymes (transient), paresthesia, renal function test abnormality, skin photosensitivity, skin rash, urticaria, venous obstruction (hepatic vein)</p></div>
<div class="block coi drugH1Div" id="F156208"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to dacarbazine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Prior severe myelosuppression.</p></div>
<div class="block war drugH1Div" id="F156191"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: May occur following dacarbazine administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Hematologic toxicity is the most common dacarbazine toxicity. Leukopenia and thrombocytopenia may be severe; anemia may also occur. The onset for leukopenia is ~14 days (range: 10 to 30 days) and the duration is ~1 to 3 weeks. The onset for thrombocytopenia is ~18 days (range: 12 to 30 days) and the duration is ~1 to 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Dacarbazine is an irritant; local reactions may occur (ESMO/EONS [Pérez Fidalgo 2012]). According to the manufacturer, extravasation may result in tissue damage and severe pain.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatic necrosis has been reported with dacarbazine. Hepatotoxicity may be accompanied with hepatic vein thrombosis and hepatocellular necrosis; may be fatal. Hepatotoxicity usually occurs with combination chemotherapy, but may occur with dacarbazine alone.</p></div>
<div class="block foc drugH1Div" id="F156202"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea); 200 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F156187"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323091"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Dacarbazine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $14.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $14.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866491"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612476"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dacarbazine in combination with doxorubicin is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer by IV infusion over 15 to 60 minutes; rapid infusion may cause severe venous irritation. Dacarbazine is an irritant; local reactions may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Monitor infusion site.</p></div>
<div class="block adm drugH1Div" id="F156205"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Dacarbazine is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 15 to 60 minutes; rapid infusion may cause severe venous irritation. Other infusion durations have been reported; refer to literature and/or regimen for infusion details (may vary by protocol).</p>
<p style="text-indent:-2em;margin-left:2em;">Dacarbazine is an irritant; local reactions may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Monitor infusion site.</p></div>
<div class="block hazard drugH1Div" id="F49130967"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F156216"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from light. Extended storage information for intact vials at room temperature may be available; contact product manufacturer to obtain current recommendations. According to the manufacturer, the reconstituted solution (in the vial) should be used within 72 hours if refrigerated and 8 hours if at room temperature; however, additional stability data indicates the reconstituted solution may be stable for 24 hours at room temperature (20°C) and 96 hours refrigerated (4°C) when protected from light (El Aatmani 2002). Following dilution for infusion (in D5W or NS), solutions may be stored for up to 24 hours refrigerated (4°C) or for up to 8 hours at normal room conditions (dacarbazine is light sensitive).</p></div>
<div class="block usep drugH1Div" id="F53566334"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of malignant melanoma, Hodgkin disease (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F156278"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dacarbazine may be confused with dactinomycin, procarbazine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F156264"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F156196"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fotemustine: May enhance the adverse/toxic effect of Dacarbazine. Specifically, the risk for pulmonary toxicity (adult acute respiratory distress syndrome) may be increased. Management: Do not administer fotemustine and dacarbazine simultaneously, particularly with high doses of dacarbazine. An interval of 1 week should be left between the last dose of fotemustine and the first dose of dacarbazine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: May enhance the adverse/toxic effect of Dacarbazine. SORAfenib may increase serum concentrations of the active metabolite(s) of Dacarbazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56526183"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Dacarbazine is a component of the ABVD regimen used for the treatment of Hodgkin lymphoma; there may be a low risk of amenorrhea and an intermediate risk of azoospermia associated with therapy. Fertility preservation can be discussed prior to therapy (ESMO [Lambertini 2020]; Traila 2018).</p></div>
<div class="block pri drugH1Div" id="F5571043"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Teratogenic effects were observed in animal reproduction studies. Outcome data following maternal use of dacarbazine primarily as part of a regimen for the treatment of Hodgkin lymphoma during pregnancy is available (Avilés 2018; Cotteret 2020; Evens 2013; NTP 2013; Pinnix 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of dacarbazine may be altered (Kantrowitz-Gordon 2018).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]). An international consensus panel has published guidelines for hematologic malignancies during pregnancy. Dacarbazine is a component of the ABVD regimen, which is used for the treatment of Hodgkin lymphoma. If treatment cannot be deferred until after delivery in patients with early stage Hodgkin lymphoma, ABVD may be administered safely and effectively in the latter phase of pregnancy (based on limited data); for patients with advanced-stage disease, ABVD can be administered in the second and third trimesters (Lishner 2016).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53566335"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential (neutrophils, hemoglobin, platelets); LFTs.</p></div>
<div class="block pha drugH1Div" id="F156190"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dacarbazine is an alkylating agent which is converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide] via the cytochrome P450 system. The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O<sup>6</sup>, N<sup>7</sup> guanine positions which lead to DNA double strand breaks and apoptosis. Dacarbazine is non-cell cycle specific (Marchesi 2007).</p></div>
<div class="block phk drugH1Div" id="F156207"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Exceeds total body water; suggesting binding to some tissue (probably liver) (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic to the active metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide]</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Biphasic: Initial: 19 minutes, 55 minutes (renal and hepatic dysfunction); Terminal: 5 hours, 7.2 hours (renal and hepatic dysfunction)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~40%; as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F156210"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina Filaxis | Oncocarbil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin lipomed | Dacarbazin Medac | Dtic-dome</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine Sandoz</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dtic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">D.t.i. | Dacarb | Dacarbazina | Fauldacar</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina | Dacarbazina kampar | Deticene</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Al quibazina | Carbaven | Dacarbazina | Dacarbazine medac | Daracina | Deticene | Tiferomed</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin | Dacarbazine medac | Dtic</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin lipomed | Detimedac | Dtic</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina | Deticene</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin Medac | Dacmed | Deticene</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina almirall | Dacarbazina medac</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Oncodac</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine lipomed | Dacarbazine medac | Dacatic</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine Dci | Dacarbazine lipomed | Dacarbazine medac | Deticene</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine medac | Dacarbazine/medac | Dacarbion | Deticene</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine lipomed | Dacin lipomed | Dakarbazin | Dakarbazin medac | Deticene</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine medac</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Celdaz | Dabaz | Dacarzine | Dazine | Decarb | Zicarb</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina lipomed | Dacarbazina medac | Deticene</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Deticene | Deticin | Detimedac | DTI | Dtic-dome</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Celdaz | Dacarbazin | Dacarbazine medac | Deticene | Detimedac | Dtic</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin Medac | Deticene | Dtic</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acocarb | Dacarbazina | Deticeme | Detilem | Ifadac | Tiferomed</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin | Dacarbazine medac | Deticene</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine lipomed | Dacarbazine medac</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina | Deticene | Oncocarbil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Arzi | Duticin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Darbazine | Decarb</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin | Dacarbazine medac | Dacin | Deticene | Detimedac | Dtic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine | Dtic-dome</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina | Deticene | Detimedac | Fauldetic</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina cipla | Dacarbazina fusa | Dacarzin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina lipomed | Dacarbazine medac | Daltrizen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin | Dacarbazine lens | Dacarbazine medac | Dakarbazin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine | Dacarbazine medac | Dacin | Deticene</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine medac</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin | Dacarbazine App | Dacarbazine lipomed | Dacin | Detimedac | DTIC-Dome</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin | Dakarbazin medac</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazine medac | Dacmed</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dacin | Deticene | Detimedac</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dakarbaz | Deticene</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dtic-dome</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazin | Dacarbazin Medac | Dacarbazine lens | Dacin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dacarbazina | Dacarbazina Filaxis | Dacarzin | Oncocarbil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dacin | Daraz | Dtic-dome</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Decarb</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Arzi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8315425">
<a name="8315425"></a>Antman K, Crowley J, Balcerzak SP, et al, “An Intergroup Phase III Randomized Study of Doxorubicin and Dacarbazine With or Without Ifosfamide and Mesna in Advanced Soft Tissue and Bone Sarcomas,” <i>J Clin Oncol</i>, 1993, 11(7):1276-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/8315425/pubmed" id="8315425" target="_blank">8315425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9529020">
<a name="9529020"></a>Antman K, Crowley J, Balcerzak SP, et al, “A Southwest Oncology Group and Cancer and Leukemia Group B phase II Study of Doxorubicin, Dacarbazine, Ifosfamide, and Mesna in Adults With Advanced Osteosarcoma, Ewing's Sarcoma, and Rhabdomyosarcoma,” <i>Cancer</i>, 1998, 82(7):1288-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/9529020/pubmed" id="9529020" target="_blank">9529020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29326803">
<a name="29326803"></a>Avilés A, Nambo MJ, Neri N. Treatment of early stages Hodgkin lymphoma during pregnancy. <i>Mediterr J Hematol Infect Dis</i>. 2018;10(1):e2018006. doi:10.4084/MJHID.2018.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/29326803/pubmed" id="29326803" target="_blank">29326803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15199092">
<a name="15199092"></a>Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. <i>J Clin Oncol</i>. 2004;22(14):2835-2841. doi: 10.1200/JCO.2004.12.170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/15199092/pubmed" id="15199092" target="_blank">15199092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1384143">
<a name="1384143"></a>Bonfante V, Santoro A, Viviani S, et al, “ABVD in the Treatment of Hodgkin's Disease,” <i>Semin Oncol</i>, 1992, 19(2 Suppl 5):38-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/1384143/pubmed" id="1384143" target="_blank">1384143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10561349">
<a name="10561349"></a>Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. <i>J Clin Oncol</i>. 1999;17(9):2745-2751. doi:10.1200/JCO.1999.17.9.2745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/10561349/pubmed" id="10561349" target="_blank">10561349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25556147">
<a name="25556147"></a>Clarkson DM, Harvey R, Sheepy D. Light protection of chemotherapy drugs for infusion. <i>Med Eng Phys</i>. 2015;37(2):233-238. doi:10.1016/j.medengphy.2014.11.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/25556147/pubmed" id="25556147" target="_blank">25556147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687059">
<a name="17687059"></a>Cohen V, Jellinek SP, Teperikidis L, et al. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/17687059/pubmed" id="17687059" target="_blank">17687059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29224502">
<a name="29224502"></a>Connors JM, Jurczak W, Straus DJ, et al; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma [published correction appears in: <i>N Engl J Med</i>. 2018;378(9):878.]. <i>N Engl J Med</i>. 2018;378(4):331-344. doi: 10.1056/NEJMoa1708984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/29224502/pubmed" id="29224502" target="_blank">29224502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32306909">
<a name="32306909"></a>Cotteret C, Pham YV, Marcais A, Driessen M, Cisternino S, Schlatter J. Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report. <i>BMC Pregnancy Childbirth</i>. 2020;20(1):231. doi:10.1186/s12884-020-02928-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/32306909/pubmed" id="32306909" target="_blank">32306909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dacarbazine.1">
<a name="Dacarbazine.1"></a>Dacarbazine [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dacarbazine.2">
<a name="Dacarbazine.2"></a>Dacarbazine for injection [product monograph] Saint-Laurent, Quebec, Canada: Hospira Healthcare Corporation; December 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35187850">
<a name="35187850"></a>de Armas S, Huertas-Ayala C, Chan RY, et al. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. <i>Pediatr Blood Cancer</i>. 2022;69(5):e29601. doi:10.1002/pbc.29601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/35187850/pubmed" id="35187850" target="_blank">35187850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12132562">
<a name="12132562"></a>El Aatmani M1, Poujol S, Astre C, et al. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. <i>Am J Health Syst Pharm</i>. 2002;59(14):1351-1356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/12132562/pubmed" id="12132562" target="_blank">12132562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17606976">
<a name="17606976"></a>Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. <i>J Clin Oncol.</i> 2007;25(23):3495-3502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/17606976/pubmed" id="17606976" target="_blank">17606976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818855">
<a name="20818855"></a>Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. <i>N Engl J Med</i>. 2010;363(7):640-652. doi: 10.1056/NEJMoa1000067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/20818855/pubmed" id="20818855" target="_blank">20818855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24043736">
<a name="24043736"></a>Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. <i>J Clin Oncol</i>. 2013;31(32):4132-4139. doi:10.1200/JCO.2013.49.8220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/24043736/pubmed" id="24043736" target="_blank">24043736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25332243">
<a name="25332243"></a>Flaherty LE, Othus M, Atkins MB, et al. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>J Clin Oncol.</i> 2014;32(33):3771-3778. doi:10.1200/JCO.2013.53.1590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/25332243/pubmed" id="25332243" target="_blank">25332243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21606430">
<a name="21606430"></a>García-Del-Muro X, López-Pousa A, Maurel J, et al; Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. <i>J Clin Oncol</i>. 2011;29(18):2528-2533. doi:10.1200/JCO.2010.33.6107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/21606430/pubmed" id="21606430" target="_blank">21606430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35584865">
<a name="35584865"></a>Hochberg J, Basso J, Shi Q, et al. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial. <i>J Immunother Cancer</i>. 2022;10(5):e004445. doi:10.1136/jitc-2021-004445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/35584865/pubmed" id="35584865" target="_blank">35584865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18780317">
<a name="18780317"></a>Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. <i>Cancer.</i> 2008;113(8):2020-2028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/18780317/pubmed" id="18780317" target="_blank">18780317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9508171">
<a name="9508171"></a>Hutchinson RJ, Fryer CJ, Davis PC, et al, “MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin's Disease in Children: Results of the Children's Cancer Group Phase III Trial,” <i>J Clin Oncol</i>, 1998, 16(3):897-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/9508171/pubmed" id="9508171" target="_blank">9508171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27332902">
<a name="27332902"></a>Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. <i>N Engl J Med</i>. 2016;374(25):2419-2429. doi:10.1056/NEJMoa1510093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/27332902/pubmed" id="27332902" target="_blank">27332902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29305638">
<a name="29305638"></a>Kantrowitz-Gordon I, Hays K, Kayode O, et al. Pharmacokinetics of dacarbazine (DTIC) in pregnancy. <i>Cancer Chemother Pharmacol</i>. 2018;81(3):455-460. doi:10.1007/s00280-017-3511-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/29305638/pubmed" id="29305638" target="_blank">29305638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE and Dorr RT, "Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function," <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>J Clin Oncol.</i> 2016;34(5):501-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17897837">
<a name="17897837"></a>Marchesi F, Turriziani M, Tortorelli G, et al, “Triazene Compounds: Mechanism of Action and Related DNA Repair Systems,” <i>Pharmacol Res</i>, 2007, 56(4):275-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/17897837/pubmed" id="17897837" target="_blank">17897837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895479">
<a name="34895479"></a>Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. <i>Lancet Oncol</i>. 2022;23(1):125-137. doi:10.1016/S1470-2045(21)00470-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/34895479/pubmed" id="34895479" target="_blank">34895479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33826362">
<a name="33826362"></a>Metzger ML, Link MP, Billett AL, et al. Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation. <i>J Clin Oncol</i>. 2021;39(20):2276-2283. doi:10.1200/JCO.20.03286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/33826362/pubmed" id="33826362" target="_blank">33826362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837968">
<a name="15837968"></a>Meyer RM, Gospodarowicz MK, Connors JM, et al, “Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group,” <i>J Clin Oncol</i>, 2005, 23(21):4634-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/15837968/pubmed" id="15837968" target="_blank">15837968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10623706">
<a name="10623706"></a>Middleton MR, Grob JJ, Aaronson N, et al, “Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma,” <i>J Clin Oncol</i>, 2000, 18(1):158-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/10623706/pubmed" id="10623706" target="_blank">10623706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736875">
<a name="24736875"></a>National Toxicology Program. NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. <i>NTP Monogr</i>. 2013;(2):i-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/24736875/pubmed" id="24736875" target="_blank">24736875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10952773">
<a name="10952773"></a>Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC). <i>Br J Cancer</i>. 2000;83(6):715-718. doi:10.1054/bjoc.2000.1314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/10952773/pubmed" id="10952773" target="_blank">10952773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7826911">
<a name="7826911"></a>Orlandi F, Caraci P, Berruti A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. <i>Ann Oncol. </i>1994;5(8):763-765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/7826911/pubmed" id="7826911" target="_blank">7826911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2013;24 Suppl 6:vi160-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. <i>Ann Oncol.</i> 2012;23(Suppl 7):vii167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perry.2012">
<a name="Perry.2012"></a>Perry MC. Chemotherapeutic agents: Dacarbazine. <i>The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27227654">
<a name="27227654"></a>Pinnix CC, Osborne EM, Chihara D, et al. Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy. <i>JAMA Oncol</i>. 2016;2(8):1065-1069. doi:10.1001/jamaoncol.2016.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/27227654/pubmed" id="27227654" target="_blank">27227654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11583197">
<a name="11583197"></a>Ramanathan RK, Cnaan A, Hahn RG, et al, “Phase II Trial of Dacarbazine (DTIC) in Advanced Pancreatic Islet Cell Carcinoma, Study of the Eastern Cooperative Oncology Group-E6282,” <i>Ann Oncol</i>, 2001, 12(8):1139-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/11583197/pubmed" id="11583197" target="_blank">11583197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21639810">
<a name="21639810"></a>Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>N Engl J Med</i>. 2011;364(26):2517-2526. doi:10.1056/NEJMoa1104621<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/21639810/pubmed" id="21639810" target="_blank">21639810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8683240">
<a name="8683240"></a>Rusthoven JJ, Quirt IC, Iscoe NA, et al, “Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Response Rates of Carmustine, Dacarbazine, and Cisplatin With and Without Tamoxifen in Patients With Metastatic Melanoma. National Cancer Institute of Canada Clinical Trials Group” <i>J Clin Oncol</i>, 1996, 14(7):2083-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/8683240/pubmed" id="8683240" target="_blank">8683240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7530987">
<a name="7530987"></a>Schlumberger M, Abdelmoumene N, Delisle MJ, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). <i>Br J Cancer.</i> 1995;71(2):363-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/7530987/pubmed" id="7530987" target="_blank">7530987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15315964">
<a name="15315964"></a>Straus DJ, Portlock CS, Qin J, et al, “Results of a Prospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for Stages I, II, and IIIA Nonbulky Hodgkin Disease,” <i>Blood</i>, 2004, 104(12):3483-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/15315964/pubmed" id="15315964" target="_blank">15315964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29942153">
<a name="29942153"></a>Traila A, Dima D, Achimas-Cadariu P, Micu R. Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era. <i>Cancer Manag Res</i>. 2018;10:1517-1526. doi:10.2147/CMAR.S154819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/29942153/pubmed" id="29942153" target="_blank">29942153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2016">
<a name="HHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25810047">
<a name="25810047"></a>Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.<i> Thyroid.</i> 2015;25(6):567-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/25810047/pubmed" id="25810047" target="_blank">25810047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8293411">
<a name="8293411"></a>Wu LT, Averbuch SD, Ball DW, et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. <i>Cancer.</i> 1994;73(2):432-436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/8293411/pubmed" id="8293411" target="_blank">8293411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2067035">
<a name="2067035"></a>Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. <i>J Natl Cancer Inst</i>. 1991;83(13):926-932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dacarbazine-pediatric-drug-information/abstract-text/2067035/pubmed" id="2067035" target="_blank">2067035</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13200 Version 265.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
